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Abstract: We previously discovered that single nucleotide polymorphisms (SNPs) in PTPN2/22 (T-cell
negative-regulators) occur in 78% of rheumatoid arthritis (RA), along with Mycobacterium avium
paratuberculosis (MAP) infection in 33% of patients. In Crohn’s disease, we reported that SNPs in TNFα
and receptors (TNFRSF1A/TNFRSF1B) benefited intracellular MAP-survival, increased infection,
and elevated inflammatory response mimicking the poor response to anti-TNFα treatment in some
patients. Here, we studied the frequency and effects of SNPs in TNFα/TNFRSF1A/TNFRSF1B in
RA including gene expression, MAP infection, and osteoporosis marker levels in blood (54 RA and
48 healthy controls). TNFα:rs1800629 (GA) was detected in 19/48 (40%) RA and 8/54 (15%) controls
(p-value < 0.05, odds ratio (OR) = 3.6, 95% CI: 1.37–9.54). TNFRS1B:rs3397 (CT) was detected in
21/48 (44%) RA and 10/54 (19%) controls (p-value < 0.05, OR = 4.43, 95% CI: 1.73–11.33). In RA, rs3397
downregulated TNFRSF1B expression (CC > CT (0.34 ± 0.14) and CC > TT (0.27 ± 0.12)), compared
to wildtype CC (0.51 ± 0.17), p-value < 0.05. MAP DNA was detected significantly in 17/48 (35.4%)
RA compared to 11/54 (20.4%) controls (p-value < 0.05, OR = 2.14, 95% CI: 1.12–5.20). The average
osteocalcin level was significantly lower (p-value < 0.05) in RA (2.70 ± 0.87 ng/mL), RA + MAP
(0.60 ± 0.31 ng/mL), RA + TNFRSF1B:rs3397 (TT) (0.67 ± 0.35 ng/mL), compared to the healthy control
(5.31 ± 1.39 ng/mL), and MAP-free RA (3.85 ± 1.31 ng/mL). Overall, rs3397 appears to downregulate
TNFRSF1B, increase MAP infection, worsen inflammation, and cause osteocalcin deficiency and
possibly osteoporosis in RA.
Keywords: rheumatoid arthritis; Mycobacterium paratuberculosis; osteocalcin; osteoporosis;
MAP; RA
1. Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disorder which affects the joints and results
in tearing of articular cartilage [1]. Patients suffering from RA are also characterized by having
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lower bone mineral density, and higher risk of fractures [1–5]. These symptoms most often lead to
osteoporosis, which has been linked to vitamin D deficiency and prolonged exposure to corticosteroids
treatment [6,7].
The elevated level of pro-inflammatory cytokines, mainly tumor necrosis factor alpha (TNFα),
in RA blood has negative effects on osteoclast paracrine stimulation, which leads to bone resorption
as seen in osteoporosis [8]. Several studies have shown that increasing osteoclastic activity plays
a major role in the development of osteoporosis in RA. For example, Gough et al. reported that
bone resorption biomarkers were elevated in RA patients who were suffering from low bone mineral
density, which resulted in further evidence that linked osteoclast activity with bone resorption in
RA [9]. Although the underlining cause of bone resorption abnormality is still debated, genetic
factors such as single nucleotide polymorphisms (SNPs) and environmental triggers are most likely
involved in the disease process [10]. Most recently, we reported that the bone biomarker osteocalcin
level was low in Crohn’s disease (CD), an inflammatory bowel disease with established association
with genetic predisposition and environmental triggers such as Mycobacterium avium subspecies
paratuberculosis (MAP) [10]. Specifically, we observed that the blood levels of active osteocalcin was
reduced, whereas the undercarboxylated osteocalcin (ucOC) level was elevated in CD, compared to
healthy individuals [10]. Most importantly, the significant decrease in the osteocalcin level in CD blood
was associated with MAP infection in these patients. These interesting data suggest a possible role for
the combined inflammatory status and MAP infection and the development of osteoporosis in CD
patients with key mutations. We further investigated such correlation and we reported that:
SNPs in TNF Receptor Superfamily Member 1A/1B (TNFRSF1A and TNFRSF1B) have
downregulated the expression of their corresponding genes significantly, which resulted in increased
susceptibility to MAP infection in CD [11].
Most recently, we discovered that MAP infection also occurred in RA patients who are
associated with SNPs in PTPN2/22, T-cell negative regulators [12]. Patients with these SNPs exhibit
hyper-proliferative T-cells, which suggests a continued hyper inflammatory response in those with
MAP infection. The combination of MAP infection, known to induce production of TNFα, and presence
of defective T-cells in RA should lead to excessive elevation of inflammatory markers, which ultimately
should impact osteoclastic activity and possibly development of osteoporosis [12]. In this study, we
focused on investigating the interaction between SNPs in TNFα and its receptors (TNFRSF1A and
TNFRSF1B), MAP infection, and active osteocalcin levels (an osteoporosis marker) in blood samples
from RA patients.
2. Materials and Methods
2.1. Clinical Samples
Peripheral blood (two 4.0 mL K2-EDTA) from 102 study participants (54 RA patients and 48 healthy
controls) were acquired from the University of Central Florida Health Center. All participants provided
written informed consent prior to enrollment, and the study was approved by the University of Central
Florida Institutional Review Board #SBE-16-12193 (approved on September 19th, 2017). RA diagnosis
was performed and reported by Dr. Shazia Beg (University of Central Florida Health) based on
approved standard American College of Rheumatology (ACR) criteria for RA diagnosis. This includes
a physical exam, imaging and laboratory tests (rheumatoid factor, C-reactive protein (CRP), erythrocyte
sedimentation rate (ESR), and anti-cyclic citrullinated peptide (AntiCCP)).
From each participant, one blood tube was processed for the presence of MAP infection, while the
second tube was used for gene expression analysis and genotyping of three SNPs in TNFα, TNFRSF1A,
and TNFRSF1B. The demographics for all participating subjects are listed in Table 1.
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Table 1. Demographics of study participants.
Diagnosis Number Age Range Average Age Gender Ratio(Male/Female %)
All Subjects 102 21–75 39 33:67
Rheumatoid Arthritis 54 22–75 49 25:75
Healthy Controls 48 20–63 30 41:59
2.2. Detection of MAP Infection in the Blood of RA Patients by nPCR
Purified white blood cells separated from the blood samples were analyzed for the presence of
MAP DNA. Genomic DNA extraction and nested PCR (nPCR) analysis were performed as described
earlier [13,14]. Briefly, nPCR was based on MAP-specific IS900 derived oligonucleotide primers.
The first round of amplification was performed using P90 (GTTCGGGGCCGTCGCTTAGG) and P91
(GAGGTCGATCGCCCACGTGA) primers at the following conditions: 95 ◦C for 5 min, then 34 cycles
of 95 ◦C for 1 min, 58 ◦C for 1.5 min, 72 ◦C for 1.5 min. Final extension of 10 min at 72 ◦C. The product
size amplified from this round was 398 bp. A second round of amplification was followed, which
involved using AV1 (ATGTGGTTGCTGTGTTGGATGG) and AV2 (CCGCCGCAATCAACTCCAG)
primers at the following conditions: 95 ◦C for 5 min, then 34 cycles of 95 ◦C for 1 min, 60 ◦C for 0.5 min,
72 ◦C for 1.5 min. Final extension of 10 min at 72 ◦C. The final PCR amplified fragment was 298 bp and
was analyzed on 2% agarose gel.
2.3. Measurement of Active Osteocalcin Level
An ELISA sandwich assay was used to measure the serum active osteocalcin level. A Life
Technologies Osteocalcin Human ELISA Kit (Life Technologies, Carlsbad, CA, USA) was used
following the manufacturer’s instructions. The absorbance readings were measured at 450 nm
wavelength and osteocalcin concentration was calculated from the generated standard curve equation
following the manufacturer’s instructions.
2.4. Identification of SNPs in TNFα, TNFRSF1A, and TNFRSF1B
Extraction and purification of genomic DNA for genotyping was performed using QIAamp DNA
Blood Mini Kit (Qiagen, Germantown, MD, USA) following the manufacturer’s instructions. TaqMan
genotyping assays (Applied Biosystems, Foster City, CA, USA) for TNFα:rs1800629, TNFRSF1A:rs767455,
and TNFRSF1B:rs3397 were performed on purified DNA samples following the manufacturer’s protocol
at the University of Florida Pharmacotherapy and Translational Research Department (Gainesville,
FL, USA). Two solutions; 2 × TaqMan master mix and 20 × assay working stock (primers with VIC
and FAM fluorophore attachment) made up the reaction mixture. Following reverse transcription
polymerase chain reaction (RT-PCR) assay (one cycle at 95 ◦C for 10 min, 92 ◦C for 15 s, and 50 cycles
at 58 ◦C for 1 min), isolated DNA samples in addition to the reaction mixture and controls were added
into a 384-well microtiter plate using the Applied Biosystems QuantStudio RT-PCR System. The plate
was analyzed for VIC and FAM fluorophores at 551 and 517 nm, respectively. Fluorescence of VIC or
FAM alone determined that the sample had allele 1 or allele 2, while VIC and FAM together determined
that the sample was heterozygous for each allele. Each selected SNP is described in Table 2.
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Table 2. Gene mutations, locations, and mutation phenotypes of single nucleotide polymorphisms





Change * Mutation Phenotype
TNF rs1800629 G > A Promoter Higher susceptibility to develop CD
TNFRSF1A rs767455 C > T Exon 4 (R > Q) Poor response to anti-TNFα treatment in CD
TNFRSF1B rs3397 C > T Exon 10 (N/A) Higher susceptibility to MAP infection in CD
* Gene mutation and location data were obtained from the National Center for Biotechnology Information
(NCBI) [15]. (R: arginine; Q: glutamine; MAP: Mycobacterium avium subspecies paratuberculosis; CD: Crohn’s
disease; MS: multiple sclerosis; N/A: unknown residue change).
2.5. RNA Extraction and Measurement of TNFα, TNFRSF1A, and TNFRSF1B Expression
Leukocytes from 1.0 mL of blood were isolated in a 2.0 mL RNase free microcentrifuge tube,
suspended in 1.0 mL of TRIzol® reagent (Invitrogen) and then subjected to RNA extraction as described
earlier [11]. RNA pellets were air-dried for 15–30 min, suspended in 20 µL of RNase free H2O,
and finally heated at 60 ◦C for 10 min. Then, 600 ng of RNA from each sample was added to 0.25 mL
tubes containing 0.2 mL of PCR reaction, 4 µL of iScript™ Reverse Transcription (Bio-Rad®), and up
to 20 µL RNase free H2O for cDNA synthesis. All tubes were then transferred to a thermal cycler
(MyGene™ Series Peltier Thermal Cycler) and run for 5 min at 25 ◦C, 20 min at 46 ◦C, and 1 min at
95 ◦C. The final concentration of cDNA synthesized for each sample was 30 ng/µL. A total volume of
1 µL of cDNA, 10 µL of Fast SYBR Green Mastermix (Thermo Fisher Scientific®), 1 µL of either TNFα,
TNFRSF1A, or TNFRSF1B PrimePCR SYBER Green Assay mix (Bio-Rad®), and 8 µL of molecular
biological grade sterile H2O were mixed in a 96-well microamp RT-PCR reaction plate. Then, 18s
RNA gene oligonucleotide primer controls (forward primer: 5′-GTA ACC CGT TGA ACC CCA TT-3′;
reverse primer: 5′-CCA TCC AAT CGG TAG CG-3′) were used in order to acquire baseline CT readings.
The RT-PCR reaction was performed using the 7500 Fast Real-Time PCR System (Applied Biosystems®).
The equation (2ˆ (−∆CT) × 1000), where ∆CT = Sample RT-PCR CT reading-18s CT baseline, was used
to calculate relative mRNA expression levels.
2.6. Statistical Analysis
All statistical tests were performed using GraphPad Prism® 8.02. For the osteocalcin level,
data are presented as mean ± SD, where a two-tailed t test was used to compare the level in RA
patients vs. healthy controls and the presence vs. the absence of MAP infection. For genotype
frequency, a two-tailed Z test and odds ratio analysis were used to compare SNPs in RA patients vs.
healthy controls. At each gene examined, SNP genotypes were categorized into four groups (major,
heterozygous, homozygous, and both heterozygous + homozygous), then each genotype group was
tested for significance within its subcategory at p < 0.05 and a 95% confidence interval (CI). For gene
expression analysis, we compared the average gene expression in RA vs. healthy control for each
gene regardless of their genotype using an unpaired two-tailed t-test at p < 0.05 and a 95% confidence
interval (CI), and then we compared individuals who carried two major alleles with others for each
SNP tested using one-way ANOVA, where a Newman–Keuls post-hoc test was selected for multiple
comparisons. For MAP infection susceptibility, infection proportions between SNP genotypes and
major alleles in the RA group was compared to the healthy control group separately using a two-tailed
Z test at p < 0.05. Age and gender were not included as covariates, as for all data sets no age or gender
effects were observed.
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3. Results
3.1. MAP DNA Detected in RA Patients
Overall, MAP DNA was detected in the blood of 28 out of 102 (27.5%) of participating subjects.
Specifically, MAP DNA was detected in 17/48 (35.4%) RA patients and 11/54 (20.4 %) healthy controls
(p-value < 0.05, odds ratio (OR) = 2.14, 95% CI: 1.12–5.20).
3.2. Lower Active Osteocalcin Levels in RA Patients
As shown in Figure 1A, the average active osteocalcin levels in RA patients was 2.70 ± 0.87 ng/mL,
compared to 5.31 ± 1.39 ng/mL in healthy controls (p-value < 0.05).
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Figure 1. Average active osteocalcin levels among; Rheumatoid Arthritis (RA) patients and healthy
controls (A), MAP positive and MAP negative regardless of disease condition (B), RA and healthy
controls in the presence and absence of MAP infection (C). * indicates p < 0.05.
3.3. Lower Active Osteocalcin Level is Detected in MAP Positive RA Patients
As shown in Figure 1B, regardless of diagnosis, the overall average level of active osteocalcin in
the blood samples that have been determined to contain MAP DNA was 2.05 ± 0.24 ng/mL compared
to 4.94 ± 0.98 ng/mL (p-value < 0.05) in blood samples that are MAP negative. Specifically, the average
osteocalcin level in RA patients who are positive for MAP was 0.60 ± 0.31 ng/mL compared to
3.85 ± 1.31 ng/mL (p-value < 0.05) in RA patients who are negative for MAP DNA, as shown in
Figure 1C.
3.4. Frequency of SNPs in TNFα, TNFRSF1A, and TNFRSF1B in RA Patients
We have assessed 102 subjects (48 RA patients and 54 healthy controls) for one SNP in TNFα
(rs1800629), two SNPs in TNFRSF1A (rs767455 and rs4149 70), and one SNP in TNFRSF1B (rs3397).
Genotype distribution of these SNPs conveyed the Hardy–Weinberg equilibrium and are all listed
in Table 3. TNFα:rs1800629 (GG to GA) was significant in RA patients compared to healthy controls
(p-value < 0.05). Specifically, TNFα:rs1800629 was detected in 19/48 RA patients (40%) compared to
8/54 healthy controls (15%) (OR = 3.6, 95% CI: 1.37–9.54). TNFRSF1B:rs3397 (CC to CT) was detected
in 21/48 RA patients (44%) compared to 10/54 (10%) healthy controls (OR = 4.43, 95% CI: 1.73–11.33).
TNFRSF1A:rs767455 (AA to AG or GG) was not significant in RA patients.
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Table 3. Genotype frequencies of selected SNPs for RA patients and healthy controls.
Genotype RA Patients(n = 48)
Healthy Controls
(n = 54) p-value * OR 95% CI
TNFα:rs1800629
GG (Reference allele) 29 (60%) 44 (82%) 0.03
GA 19 (40%) 8 (15%) 0.02 3.6 1.37–9.54
AA 0 (0%) 2 (0%) 0.23 0.2 0.01–3.36
GA + AA 19 (40%) 10 (19%) 0.04 2.9 1.17–7.07
TNFRSF1A:rs767455
AA (Reference allele) 22 (46%) 29 (54%) 0.42
AG 20 (42%) 22 (41%) 0.47 1.2 0.53–2.73
GG 6 (12%) 3 (6%) 0.17 2.6 0.59–11.7
AG + GG 26 (54%) 25 (46%) 0.31 1.4 0.63–2.99
TNFRSF1B:rs3397
CC (Reference allele) 18 (37%) 38 (70%) 0.02
CT 21 (44%) 10 (19%) 0.03 4.43 1.73–11.3
TT 9 (19%) 6 (11%) 0.29 3.17 0.98–10.3
CT + TT 30 (62%) 16 (30%) 0.03 4 1.73–9.05
Two-tailed Z test and odds ratio analysis were used to compare the presence of SNPs in CD patients vs. healthy
controls. * p-value of < 0.05 was considered as the significance threshold. (RA: rheumatoid arthritis; SNP: single
nucleotide polymorphism; OR: odds ratio (crude); CI: confidence interval).
3.5. rs3397 Downregulates TNFRSF1B Expression in RA Patients
In general, and regardless of the presence or absence of SNPs, the average relative gene expression
for TNFα was 3-fold higher in RA patients (2.68 ± 0.34), compared to healthy subjects (0.79 ± 0.23)
(p-value < 0.05). As shown in Figure 2B,C, the relative gene expression of TNFRSF1A was 0.42 ± 0.11
in RA compared to 0.81 ± 0.14 in healthy controls (p-value < 0.05). The relative gene expression
of TNFRSF1B was 0.39 ± 0.15 in RA compared to 0.71 ± 0.13 in healthy controls (p-value < 0.05).
Most importantly, the average relative gene expression level of TNFRSF1B was significantly lower in
RA patients with rs3397 (CT: 0.34 ± 0.14 or TT: 0.27 ± 0.12) compared to RA patients with the major
genotype (CC: 0.51 ± 0.17) (p-value < 0.05), as shown in Figure 2C. On the other hand, rs767455 did not
have any significant effect on TNFRSF1A expression, as shown in Figure 2B, and the effect of rs1800629
on TNFα expression was not significant, as shown in Figure 2A.
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3.6. TNFRSF1B:rs3397 is Associated with Lower Active Osteocalcin Level in RA Patients
Among RA patients, only TNFRSF1B:rs3397 was associated with a lower active osteocalcin level.
Blood samples from patients with the CC genotype had a significantly higher level of active osteocalcin
(1.86 ± 0.61 ng/mL) (p-value < 0.05), compared to samples from patients who had the TNFRSF1B:rs3397
homozygous (TT) genotype (0.67 ± 0.35 ng/mL), as shown in Figure 3C.
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The average active osteocalcin level of healthy controls without the TNFα:rs1800629 SNP (GG
genotype) was 3.55 ± 0.61 ng/mL, compared to the heterozygous or homozygous SNPs (GA or AA
genotype), which was 1.75 ± 0.36 ng/mL, as shown in Figure 3A. Similarly, we found that healthy
controls who did not have SNP in TNFRSF1A:rs767455 (AA genotype) had an average active osteocalcin
level of 3.43 ± 0.74 ng/mL, which is significantly higher than healthy controls who had a homozygous
SNP (GG genotype), which was 0.94 ± 0.17 ng/mL (p-value < 0.05), as shown in Figure 3B.
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3.7. TNFRSF1B:rs3397 is Associated with MAP Infection in RA
Blood samples from RA patients with TNFRSF1B:rs3397 (CT or TT genotype) were significantly
positive for MAP DNA (38.1% and 66.6%, respectively), compared to blood from RA patients with
the wildtype (CC) genotype (16.7%, p-value < 0.05). Similarly, MAP DNA was detected in th blood
samples of 50% of the healthy controls with the TNFRSF1B:rs3397 (TT) genotype, compared to the
wildtype (CC) genotype of healthy controls (13.2%, p-value < 0.05), as shown in Figure 4. The detection
of MAP DNA was not significant in blood samples with TNFα:rs1800629 or TNFRSF1A:rs767455.
Additionally, we categorized RA patients into four groups depending on the treatment they were
receiving. There was no significant association between treatment option and MAP infection or
osteocalcin level, as shown in Table 4.
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Table 4. Average osteocalcin levels and MAP infection according to treatment groups among RA patients.
Treatment Group Number of PatientsReceiving Treatment MAP Infection
Average Osteocalcin
(ng/mL)
Anti-TNFα 20 6/20 (30.0%) 2.71 ± 0.82
Methotrexate 28 10/28 (35.7%) 2.49 ± 0.57
Corticosteroids 13 3/13 (23.1%) 2.98 ± 0.69
Hydroxychloroquine 9 4/9 (44.4%) 2. 3 ± 0.26
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4. Discussion
The development of osteoporosis and osteoporotic fractures are common among RA patients [1–5].
Osteoporosis is associated with a higher level of bone resorption due to inflammation, use of
glucocorticoids, and limited physical activity [16–18]. Although the mechanism of osteoporosis
development in RA patients is still unclear, recent studies have shown that osteoclasts play a major role
in the bone erosion process in patients with osteoporosis [19–22]. Osteoclast’s function is regulated by
a balance between TNFα superfamily molecules (such as osteoprotegerin (OPG)), the receptor activator
of nuclear factor κB ligand (RANKL), and TNF-related apoptosis-inducing ligand (TRAIL) [23,24].
The mechanisms involved in these interactions and cell signaling have not been elucidated.
Our group has recently established that in vitro infection of macrophages with MAP caused
more production of pro-inflammatory cytokines such as TNFα, IL-6, and IL-12 [25]. Several studies
have used gene expression profiling to demonstrate the variable response to mycobacterial infections
in vitro [26–28]. In MAP infected macrophages, expression of quiescent genes (Ephrin-A5, IL-1RA,
and IL-7Rα) was higher in comparison to other bacterial species, such as Mycobacterium avium
subspecies avium (MAA) [29]. Additionally, MAA and MAP have substantial effects on expression
of apoptosis-related genes, such as FasL and BCL10 [29]. In contrast, MAP infection led to lower
expression of major MAPK pathways, including BMP7 and CDK2 [29]. Interestingly, treatment of
MAP-infected macrophages with anti-TNFα biologics increased MAP survival and burden, and led
to excessive inflammatory response [25]. This is consistent with other studies, which reported a rise
in M. tuberculosis infection in patients on anti-TNFα treatment [30]. In this study, we confirmed the
presence of MAP infection in the blood of RA patients; the majority of these patients were on anti-TNFα
treatment. The detection rate of MAP DNA was significantly higher in RA samples compared to
healthy controls. This is consistent with our earlier report where MAP was detected in 34% of RA
patients [12].
Since MAP was associated with low active osteocalcin levels in CD in an earlier study [10], we were
able to confirm this observation in RA. The data in this study showed an association between low serum
levels of osteocalcin and MAP infection, regardless of disease status, as shown in Figure 1B. This was
further confirmed when the serum level of osteocalcin was lower in blood samples from MAP positive
controls (patients who appear to be free from CD or RA), indicating that infection by intracellular
pathogens such as MAP directly impact the osteocalcin production mechanism. A low osteocalcin
level is one of the indicators of osteoporosis. This raises a point for discussion, which requires further
research to confirm or exclude any association between infection, osteocalcin production, and possibly
osteoporosis in CD and/or RA.
The shared similarities between CD and RA, especially with regards to TNFα profiling and
anti-TNFα treatment options [31,32], have encouraged us to investigate the effects of these treatment
options on increased risk of MAP or M. tuberculosis infection and subsequent impact on bone erosions
and osteoporosis in these patients. As observed in CD, we determined that the relative expression
level of TNFα was 2.7-fold higher, while the TNFRSF1A and TNFRSF1B expression level was 1-fold
lower in RA patients compared to healthy controls. More importantly, both the CT and TT genotypes
of TNFRSF1B:rs3397 have significantly reduced gene expression. Coincidentally, MAP was detected
significantly higher in the blood of RA patients with TNFRSF1B:rs3397 compared to wildtype RA.
The data strongly associates TNFRSF1B:rs3397 with MAP infection and low osteocalcin levels in RA.
This confirms earlier findings in CD with unique SNPs in TNFα receptors (TNFRS1A:rs767455 and
TNFRS1B:rs3397) [11].
A critical point to consider in the intersection of immune response and apoptosis is the expression
of TNFRSF1A and TNFRSF1B in MAP-infected cells. MAP infection resulted in lower expression of
TNFRSF1A, while no changes in expression of TNFRSF1B were observed in infected macrophages [33].
Interestingly, TNFRSF1A has been recognized as the more pro-apoptotic gene, while TNFRSF1B
has been linked to apoptosis suppression [34]. TNFRSF1A:rs767455 and TNFRSF1B:rs3397 altered
expression of corresponding genes, leading to further downregulation, which may cause MAP-infected
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macrophages to persist with apoptosis and production of higher levels of TNFα. An elevated TNFα
level plays a crucial role in the osteoclast paracrine stimulation, which influences bone resorption
ultimately [8]. The data clearly demonstrated that dysregulated pro-inflammatory cytokine levels due
to persistent MAP infection may result in hyperactive osteoclast activity and alter osteocalcin levels,
while the SNPs affected gene expression levels.
Further genetic and functional analyses should be done in order to establish whether these SNPs
cause linkage disequilibrium with a nearby-localized gene responsible for the observed effect. It is
worth mentioning that TNFα:rs1800629 was strongly associated with the resolution of hepatitis B virus
(HBV) infection and reported in susceptibility to human papillomavirus (HPV) infection [35]. The SNP
TNFRSF1A:rs767455 was associated with susceptibility to invasive pulmonary aspergillosis (IPA) and
TNFRSF1B:rs3397 was reported in occult HBV infection in inflammatory arthritis patients [36,37].
Overall, MAP infection has significantly lowered sera levels of active osteocalcin, a major biomarker
for osteoporosis in both CD and RA patients, which confirms our earlier data, where MAP infection
decreased active osteocalcin levels in patients with CD [10]. MAP infection was more prevalent in RA
patients exhibiting SNPs in TNFα receptors (TNFRS1A:rs767455 and TNFRS1B:rs3397). Collectively,
the data supports a link between intracellular infection with MAP, SNPs in TNFα receptors, and active
osteocalcin levels. The conclusion of this study should provoke scientists to consider inflammatory
disorders and their complications as an interplay between genetic predisposition, effects of standard
treatment options, and acquired infection. A personalized treatment option should be more effective
to achieve a cure.
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